Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 3

Sponsor Class

INDUSTRY 3OTHER 2NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 501Neoplasms 304Breast Neoplasms 298Colorectal Neoplasms 230Neoplasm Metastasis 196Prostatic Neoplasms 175Ovarian Neoplasms 173Lung Neoplasms 160Multiple Myeloma 159Recurrence 134Melanoma 125Pancreatic Neoplasms 116Squamous Cell Carcinoma of Head and Neck 105Stomach Neoplasms 103Leukemia, Myeloid, Acute 102Endometrial Neoplasms 102Small Cell Lung Carcinoma 89Leukemia, Lymphocytic, Chronic, B-Cell 87Triple Negative Breast Neoplasms 85Lymphoma, Non-Hodgkin 85Carcinoma, Renal Cell 83Carcinoma, Hepatocellular 79Urinary Bladder Neoplasms 77Lymphoma, Large B-Cell, Diffuse 74Lymphoma, Follicular 68Advanced Solid Tumors 66Parkinson Disease 4, Autosomal Dominant Lewy Body 62Lymphoma 62Glioblastoma 59Head and Neck Neoplasms 57

Interventions

liposomal doxorubicin 1Taxes 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Doxorubicin 1Carboplatin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia-Lymphoma, Adult T-Cell × 90 days × Clear all
NCT06035497 2026-05-01

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Bristol-Myers Squibb

Phase 1/2 Active not recruiting
85 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Recurrence, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT02732275 2026-04-28

DS-3201b in Participants With Lymphomas

Daiichi Sankyo

Phase 1 Active not recruiting
100 enrolled
DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, B-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡